scispace - formally typeset
F

Fredrik Piehl

Researcher at Karolinska Institutet

Publications -  350
Citations -  20113

Fredrik Piehl is an academic researcher from Karolinska Institutet. The author has contributed to research in topics: Multiple sclerosis & Medicine. The author has an hindex of 63, co-authored 304 publications receiving 15648 citations. Previous affiliations of Fredrik Piehl include Johns Hopkins University & University of Gothenburg.

Papers
More filters
Journal ArticleDOI

Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis

Stephen Sawcer, +265 more
- 10 Aug 2011 - 
TL;DR: In this article, a collaborative GWAS involving 9,772 cases of European descent collected by 23 research groups working in 15 different countries, they have replicated almost all of the previously suggested associations and identified at least a further 29 novel susceptibility loci.
Journal ArticleDOI

Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis

Ashley Beecham, +206 more
- 01 Nov 2013 - 
TL;DR: This study enhances the catalog of multiple sclerosis risk variants and illustrates the value of fine mapping in the resolution of GWAS signals.
Journal ArticleDOI

Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology: A Systematic Review and Meta-analysis

Claire Bridel, +82 more
- 01 Sep 2019 - 
TL;DR: The cNfL increased with age in HC and a majority of neurological conditions, although the association was strongest in HC, and has potential to assist the differentiation of FTD from AD and PD from atypical parkinsonian syndromes.
Journal ArticleDOI

Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study

James F. Howard, +623 more
- 01 Dec 2017 - 
TL;DR: A phase 3, randomised, double-blind, placebo-controlled, multicentre study in 76 hospitals and specialised clinics across North America, Latin America, Europe, and Asia to assess the efficacy and safety of eculizumab in patients with refractory myasthenia gravis.